How to Get Leqvio (Inclisiran) in Hawaii

What Is Leqvio and Why Does It Matter for Hawaii Patients?

Leqvio (inclisiran) is a small interfering RNA (siRNA) therapy that silences PCSK9 synthesis in the liver, producing durable LDL-C reductions with only two injections per year after the loading phase. The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy. [1]

Hawaii has among the highest rates of mixed-ethnicity cardiovascular risk in the United States. Native Hawaiian and Pacific Islander adults carry disproportionately elevated rates of dyslipidemia and premature coronary artery disease, making access to newer lipid-lowering agents particularly relevant for providers on the islands. [2] Because Leqvio requires a cold-chain subcutaneous injection administered by a clinician or trained patient, the logistics of obtaining it in a geographically isolated state like Hawaii differ from mainland access.

The pooled ORION-10 and ORION-11 trials (N=3,457 total) demonstrated that inclisiran 284 mg reduced LDL-C by a time-averaged 50% versus placebo at 17 months, with a safety profile comparable to placebo. [3] That degree of LDL lowering matches the best-performing monoclonal PCSK9 inhibitors (evolocumab, alirocumab) while cutting injection burden from every two or four weeks down to twice yearly. For Hawaii patients who travel long distances to cardiology clinics, that reduced frequency matters clinically and practically.

Step 1: Find a Prescriber Licensed in Hawaii

Any MD, DO, nurse practitioner (NP), or physician assistant (PA) with an active Hawaii DEA and state license may prescribe inclisiran. Hawaii Revised Statutes Chapter 453D gives NPs full prescriptive authority, meaning a telehealth NP operating under Hawaii licensure can initiate and manage a Leqvio prescription without a physician co-signature. [4]

Telehealth is fully permitted. Hawaii enacted H.B. 1063 (2020) and subsequent telehealth parity regulations requiring commercial insurers to reimburse telehealth visits at parity with in-person care. A board-certified cardiologist or lipidologist practicing via synchronous video qualifies as a valid prescribing encounter under Hawaii Administrative Rules Title 16. [5]

When selecting a telehealth provider, confirm two things: the clinician holds an active Hawaii state license (searchable at the Hawaii Medical Board portal), and the platform can coordinate with a specialty pharmacy licensed to ship into Hawaii. HealthRX connects Hawaii patients with board-certified providers who are experienced with PCSK9-pathway agents and familiar with Hawaii-specific payer requirements.

Patients on Oahu, Maui, Hawaii Island, Kauai, Molokai, and Lanai are all eligible for telehealth prescribing. No physical proximity to a mainland provider is necessary; the prescriber simply must hold a Hawaii license.

Step 2: Gather the Required Laboratory Work

Before a prescriber can initiate inclisiran, they need a current lipid panel and baseline metabolic data. Labs drawn within the preceding 90 days are generally acceptable to both the prescriber and the payer conducting prior authorization.

Minimum required labs for most Hawaii payers:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C)
• Comprehensive metabolic panel (CMP) including hepatic function
• Thyroid-stimulating hormone (TSH) to rule out hypothyroidism as a secondary cause of elevated LDL
• HbA1c if the patient has diabetes or prediabetes
• Lipoprotein(a) [Lp(a)] if familial hypercholesterolemia is suspected

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD, initiate high-intensity statin therapy... If LDL-C remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe and, if further reduction is needed, a PCSK9 inhibitor." [6] Most Hawaii commercial payers follow this step-therapy logic directly. Inclisiran will not clear prior authorization unless documentation shows the patient has already trialed a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) and, in many cases, ezetimibe 10 mg as well.

Quest Diagnostics and LabCorp both maintain patient service centers in Honolulu and Kahului. Patients on neighbor islands may use their nearest clinical lab; results upload directly to most telehealth platforms via HL7 FHIR-compliant data sharing. [7]

Step 3: Complete the Prior Authorization

Prior authorization (PA) is the single most common delay in the inclisiran access pathway. Most commercial plans in Hawaii, including HMSA (Hawaii Medical Service Association) and Kaiser Permanente Hawaii, require PA before approving inclisiran. Hawaii Medicaid (Med-QUEST) does not currently cover inclisiran as of January 2025, meaning Medicaid beneficiaries must use the Novartis patient assistance program (discussed below) or a 503A compounding route.

Standard PA documentation checklist for Hawaii commercial payers:

1. Current fasting LDL-C value (typically must be 70 mg/dL or above for ASCVD, or 100 mg/dL or above for HeFH without ASCVD)
2. Evidence of maximally tolerated high-intensity statin for at least 90 days
3. Documentation of ezetimibe trial (many HMSA formularies require this)
4. ICD-10 diagnosis code: E78.01 (familial hypercholesterolemia, heterozygous) or I25.10 (ASCVD)
5. Prescriber attestation of statin intolerance if applicable, with chart notes supporting myopathy or hepatotoxicity
6. Letter of medical necessity signed by the prescribing clinician

Hawaii law (H.R.S. Chapter 431M) requires insurers to complete standard PA decisions within five business days of receiving a complete submission, and urgent PA within 72 hours. [8] If the PA is denied, the prescriber can request a peer-to-peer review with the plan's medical director. Denial rates for PCSK9-pathway agents dropped substantially after the 2017 ACC consensus statement, but rejections still occur when step-therapy documentation is incomplete. [9]

Step 4: Choose a Pharmacy or Compounding Route

Specialty pharmacy (brand Leqvio). Inclisiran 284 mg/1.5 mL single-dose prefilled syringe requires cold-chain handling (2 to 8 degrees Celsius). Accredo Health Group, CVS Specialty, and Walgreens Specialty Pharmacy all ship to Hawaii addresses. Shipping from the mainland to Honolulu typically takes 24 to 48 hours via overnight cold-chain courier; neighbor islands may require an additional 12 to 24 hours. Confirm cold-pack integrity upon receipt.

503A compounding pharmacies. Hawaii licenses 503A patient-specific compounding pharmacies under Hawaii Administrative Rules Title 16, Chapter 75. A licensed 503A pharmacy may compound inclisiran for a named patient when a valid prescription exists and the branded product is unavailable or cost-prohibitive. Compounded inclisiran is not FDA-approved and carries different quality-assurance standards than the Novartis product; discuss this distinction with your prescriber. [10] No 503B outsourcing facility currently lists inclisiran on its FDA-registered bulk drug list, so 503B is not a current option.

Cost and patient assistance. Without insurance, the list price of Leqvio runs approximately $3,300 per injection. Novartis offers the Leqvio Together patient support program, which can reduce out-of-pocket costs to as low as $0 per dose for eligible commercially insured patients. Medicare Part B covers inclisiran when administered in a physician office setting under J-code J3590 (unclassified biological). [11] Medicare Advantage plans in Hawaii may require separate formulary review.

Step 5: Arrange Administration

Inclisiran is a subcutaneous injection administered by a clinician. The FDA label specifies that it should be given in the abdomen, upper arm, or thigh by a healthcare provider, not self-injected. [1] For Hawaii patients, this means coordinating with a local provider, clinic, or infusion center for the actual injection appointment, even if the prescription was written via telehealth.

Administration options in Hawaii:

• Primary care physician or cardiologist office (most common on Oahu)
• Federally Qualified Health Centers (FQHCs) such as Kokua Kalihi Valley or Waianae Coast Comprehensive Health Center
• Kaiser Permanente Hawaii outpatient clinic for Kaiser members
• Visiting nurse services for homebound patients on neighbor islands

The injection takes under two minutes. The Day 1 and Day 90 loading doses establish the therapeutic effect; after that, injections occur every six months. Missing a six-month dose by up to three months is acceptable per the FDA label; the next dose can then be rescheduled from that administration date. [1]

Clinical data from ORION-9 (N=482 HeFH patients) showed that inclisiran reduced LDL-C by 39.7% from baseline versus placebo at Day 510, with P<0.001 and a safety profile indistinguishable from placebo on major adverse events. [12] For HeFH patients who may be managing LDL-C levels above 190 mg/dL despite statins, that magnitude of reduction can be the difference between goal and non-goal LDL-C.

Managing Your Leqvio Therapy Long-Term in Hawaii

After the first two doses, ongoing management in Hawaii is straightforward. Your prescriber should order a fasting lipid panel four to eight weeks after each injection to confirm adequate LDL-C response. The ACC/AHA guideline recommends a target LDL-C below 70 mg/dL for very high-risk ASCVD patients, and below 100 mg/dL for high-risk patients without prior events. [6]

Inclisiran does not require liver function monitoring beyond the standard annual CMP, as hepatotoxicity was not observed at higher-than-background rates in the ORION phase III program. [3] Injection-site reactions occurred in 2.6% of inclisiran recipients versus 1.8% of placebo recipients in the pooled ORION-10/11 analysis; these were mild and transient. [3]

If your Hawaii-based payer requires annual PA renewals, your telehealth provider can submit updated lipid panels and clinical notes electronically. Hawaii's telehealth parity law means that a follow-up video visit generates a billable record acceptable to most payers for PA renewal documentation. [5]

Patients transferring from the mainland with an existing inclisiran prescription should contact their specialty pharmacy to update the ship-to address. Because inclisiran requires clinician administration, a prescription transfer also involves identifying a Hawaii-based administration site. Your telehealth prescriber can generate a new Hawaii-addressed prescription and coordinate with an in-state clinic for injection scheduling. Most specialty pharmacies can execute this transfer within three to five business days.

The Cardiovascular Evidence Base Behind the Prescription

Prescribers in Hawaii writing inclisiran need to be grounded in the phase III trial data, and patients benefit from understanding why this drug was chosen.

ORION-10 enrolled 1,561 patients with ASCVD on maximally tolerated statin therapy and randomized them to inclisiran 284 mg or placebo at Day 1, Day 90, and every six months. At Day 510, inclisiran reduced LDL-C by 52.3% versus placebo (P<0.001). [3] ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents and showed a 49.9% LDL-C reduction with the same protocol. [3] Both trials were published in the New England Journal of Medicine in 2020.

The European ORION-4 cardiovascular outcomes trial (N=15,000, ongoing at the time of publication) is expected to provide direct MACE data. Cardiovascular outcomes data for inclisiran remain an active area; the ACC 2022 Expert Consensus Decision Pathway notes that LDL-C reduction of the magnitude seen in ORION-10/11 is "expected to translate to MACE reduction based on the established LDL hypothesis." [13]

For Hawaii patients with HeFH, the 2023 National Lipid Association (NLA) guidelines recommend PCSK9 inhibition (including siRNA approaches) for patients with HeFH who remain above LDL-C goal on statin plus ezetimibe. [14] That recommendation provides the clinical rationale that supports PA approval by Hawaii commercial payers.

The FOURIER trial (evolocumab, N=27,564) showed a 15% relative risk reduction in MACE with approximately 59% LDL-C lowering, reinforcing the clinical benefit associated with deep LDL-C reductions via PCSK9 inhibition. [15] While FOURIER evaluated a monoclonal antibody rather than inclisiran, the underlying mechanism of PCSK9 inhibition is shared, and Hawaii payers use FOURIER data when considering the class broadly.

Telehealth Workflow for Hawaii Patients: A Practical Overview

A Hawaii patient seeking inclisiran through HealthRX follows a defined sequence. The patient completes an online intake form listing current medications, prior statin history, most recent lipid values, and insurance information. A board-certified provider reviews the intake and either approves a direct consult or requests lab work first.

During the video consult, the provider reviews the full lipid history, confirms the ASCVD or HeFH diagnosis, and documents statin tolerance status. If inclisiran is appropriate, the provider generates the prescription and initiates the PA submission to the patient's Hawaii insurer simultaneously. The provider also identifies the nearest Hawaii-based administration site for the patient.

Once PA is approved (typically two to seven business days for standard requests under Hawaii law), the specialty pharmacy ships the medication to the administration site. The patient schedules an injection appointment. Total elapsed time from intake to first injection: two to six weeks, depending on payer response time and neighbor-island shipping logistics.

For patients whose PA is denied on the first attempt, HealthRX providers conduct peer-to-peer appeals with the Hawaii plan medical director within 48 hours of denial notification. First-level appeals succeed in a substantial proportion of cases when the clinical record clearly documents step-therapy compliance.